Cargando…

Assessment of CA-125 First-Trimester Values as a Potential Screening Marker for Pre-Eclampsia

Background: Pre-eclampsia is a major public health issue. Current screening methods are based on maternal characteristics and medical history, but complex predictive models combining different clinical and biochemical markers have been proposed. However, although their accuracy is high, the implemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Balint, Oana, Secosan, Cristina, Pirtea, Laurentiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222554/
https://www.ncbi.nlm.nih.gov/pubmed/37241123
http://dx.doi.org/10.3390/medicina59050891
_version_ 1785049726902599680
author Balint, Oana
Secosan, Cristina
Pirtea, Laurentiu
author_facet Balint, Oana
Secosan, Cristina
Pirtea, Laurentiu
author_sort Balint, Oana
collection PubMed
description Background: Pre-eclampsia is a major public health issue. Current screening methods are based on maternal characteristics and medical history, but complex predictive models combining different clinical and biochemical markers have been proposed. However, although their accuracy is high, the implementation of these models in clinical practice is not always feasible, especially in low- and middle-resource settings. CA-125 is a tumoral marker, accessible and cheap, with proven potential as a severity marker in the third trimester of pregnancy in pre-eclamptic women. Assessment of its use as a first-trimester marker is necessary. Methods: This observational study involved fifty pregnant women between 11 and 14 weeks of pregnancy. Clinical and biochemical markers (PAPP-A), known for their value in pre-eclampsia screening, were recorded for every patient as well as first-trimester value of CA-125 and third-trimester data regarding blood pressure and pregnancy outcome. Results: No statistical correlation between CA-125 and first-trimester markers was observed except with PAPP-A, with which it exhibited a positive correlation. Additionally, no correlation was made between it and third-trimester blood pressure or pregnancy outcomes. Conclusions: CA-125 first-trimester values do not represent a valuable marker for pre-eclampsia screening. Further research on identifying an accessible and cheap marker to improve pre-eclampsia screening in low- and middle-income settings is needed.
format Online
Article
Text
id pubmed-10222554
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102225542023-05-28 Assessment of CA-125 First-Trimester Values as a Potential Screening Marker for Pre-Eclampsia Balint, Oana Secosan, Cristina Pirtea, Laurentiu Medicina (Kaunas) Article Background: Pre-eclampsia is a major public health issue. Current screening methods are based on maternal characteristics and medical history, but complex predictive models combining different clinical and biochemical markers have been proposed. However, although their accuracy is high, the implementation of these models in clinical practice is not always feasible, especially in low- and middle-resource settings. CA-125 is a tumoral marker, accessible and cheap, with proven potential as a severity marker in the third trimester of pregnancy in pre-eclamptic women. Assessment of its use as a first-trimester marker is necessary. Methods: This observational study involved fifty pregnant women between 11 and 14 weeks of pregnancy. Clinical and biochemical markers (PAPP-A), known for their value in pre-eclampsia screening, were recorded for every patient as well as first-trimester value of CA-125 and third-trimester data regarding blood pressure and pregnancy outcome. Results: No statistical correlation between CA-125 and first-trimester markers was observed except with PAPP-A, with which it exhibited a positive correlation. Additionally, no correlation was made between it and third-trimester blood pressure or pregnancy outcomes. Conclusions: CA-125 first-trimester values do not represent a valuable marker for pre-eclampsia screening. Further research on identifying an accessible and cheap marker to improve pre-eclampsia screening in low- and middle-income settings is needed. MDPI 2023-05-06 /pmc/articles/PMC10222554/ /pubmed/37241123 http://dx.doi.org/10.3390/medicina59050891 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Balint, Oana
Secosan, Cristina
Pirtea, Laurentiu
Assessment of CA-125 First-Trimester Values as a Potential Screening Marker for Pre-Eclampsia
title Assessment of CA-125 First-Trimester Values as a Potential Screening Marker for Pre-Eclampsia
title_full Assessment of CA-125 First-Trimester Values as a Potential Screening Marker for Pre-Eclampsia
title_fullStr Assessment of CA-125 First-Trimester Values as a Potential Screening Marker for Pre-Eclampsia
title_full_unstemmed Assessment of CA-125 First-Trimester Values as a Potential Screening Marker for Pre-Eclampsia
title_short Assessment of CA-125 First-Trimester Values as a Potential Screening Marker for Pre-Eclampsia
title_sort assessment of ca-125 first-trimester values as a potential screening marker for pre-eclampsia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222554/
https://www.ncbi.nlm.nih.gov/pubmed/37241123
http://dx.doi.org/10.3390/medicina59050891
work_keys_str_mv AT balintoana assessmentofca125firsttrimestervaluesasapotentialscreeningmarkerforpreeclampsia
AT secosancristina assessmentofca125firsttrimestervaluesasapotentialscreeningmarkerforpreeclampsia
AT pirtealaurentiu assessmentofca125firsttrimestervaluesasapotentialscreeningmarkerforpreeclampsia